MRNS Insider Trading Activity and SEC Form 4 Filings
MRNS insider trading summary
No open-market insider purchases or sales of Marinus Pharmaceuticals, Inc. (MRNS) have been reported on SEC Form 4 in the past 12 months.
Latest MRNS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 21, 2025 | Elan Ezickson | Insider | Sell | $864 (1,600 @ $0.54) |
| Jan 21, 2025 | Marvin Johnson | Insider | Sell | $869 (1,610 @ $0.54) |
| Aug 14, 2024 | Scott Braunstein | Chairman and CEO | Buy | $7K (5,933 @ $1.10) |
| Aug 5, 2024 | Christina Shafer | Chief Commercial Officer | Sell | $4K (3,820 @ $1.14) |
| Aug 5, 2024 | Martha E Manning | SVP, Gen. Counsel & Corp. Sec. | Sell | $4K (3,621 @ $1.13) |
| Aug 5, 2024 | Steven Pfanstiel | CFO and COO | Sell | $5K (4,657 @ $1.13) |
| Aug 5, 2024 | Scott Braunstein | Chairman and CEO | Sell | $14K (12,145 @ $1.13) |
| Aug 5, 2024 | Joseph Hulihan | Chief Medical Officer | Sell | $5K (4,828 @ $1.13) |
| Feb 20, 2024 | Martha E Manning | SVP, Gen. Counsel & Corp. Sec. | Sell | $18K (1,894 @ $9.57) |
| Feb 20, 2024 | Christina Shafer | Chief Commercial Officer | Sell | $21K (2,153 @ $9.56) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.